ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage specialty biopharmaceutical company that completed a SPAC business combination and began trading on the Nasdaq in 2022. The company focuses on developing first-in-class therapeutics for patients with inflammatory and renal diseases, with lead programs including IC 100, an inflammasome ASC inhibitor in development for neuroinflammation, and VAR 200, a cholesterol efflux modulator targeting focal segmental glomerulosclerosis. ZyVersa filed a Form 10-Q on November 14, 2022, reflecting its post-merger standing as a public reporting company operating in the healthcare and biotechnology sector. For complete filing history, deal timelines, and pipeline analytics on ZyVersa and the broader de-SPAC universe, create a free account on SpacDesk.